An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that its Chief Executive Officer, Shawn Singh, will participate in a panel discussion regarding emerging therapies for psychiatric disorders and host one-on-one meetings at the Cantor Neurology & Psychiatry Conference taking place in San Francisco on October 6 and 7, 2022.
Panel Details
Title: Emerging broad pipeline for psychiatric indications does not weigh on our mind
Date: Friday, October 7, 2022 Time: 7:50 a.m. Pacific Time
The panel presentation will be available only to conference participants and no webcast will be available. Investors interested in arranging a one-on-one meeting during the conference should contact the Cantor Fitzgerald conference coordinator.
About Vistagen
Vistagen (Nasdaq: VTGN) is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other CNS disorders. Vistagen is advancing therapeutics with the potential to be faster-acting, and with fewer side effects and safety concerns, than those that are currently available. PH94B and PH10 belong to a new class of drugs known as pherines, which are investigational neuroactive steroid nasal sprays designed with a novel rapid-onset mechanism of action that activates chemosensory neurons in the nasal passages and can impact the olfactory-amygdala neural circuits without systemic distribution or direct activity on CNS neurons in the brain. Vistagen is passionate about transforming mental health care and redefining what is possible in the treatment of anxiety and depression. Connect at www.Vistagen.com.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.